Skip to main content
Premium Trial:

Request an Annual Quote

BGI Bloodstream Pathogen Nucleic Acid Detection Kit Gets CE Mark

NEW YORK – BGI said last week that its nucleic acid detection kit for bloodstream infection pathogens has received the CE mark.

The kit, developed by BGI Patho-Genesis Pharmaceutical Technology, a holding subsidiary of BGI Genomics, uses combinatorial probe-anchor synthesis technology to prepare libraries for metagenomic sequencing to detect pathogens that cause bloodstream infections. It is designed to construct a sequencing library directly from clinical samples.

The sequencing data is analyzed using dedicated software and compared to a curated microbial genome reference database for the detection of pathogens including bacteria, fungi, viruses, and parasites. 

According to Shenzhen, China-based BGI, the kit has already been used widely in clinical practice to identify pathogens causing bloodstream infection.